These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 26412802)

  • 21. Pharmacodynamics, pharmacokinetics, safety and tolerability of the novel dual glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 agonist RG7697 after single subcutaneous administration in healthy subjects.
    Portron A; Jadidi S; Sarkar N; DiMarchi R; Schmitt C
    Diabetes Obes Metab; 2017 Oct; 19(10):1446-1453. PubMed ID: 28741871
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Subcutaneous Injection Depth Does Not Affect the Pharmacokinetics or Glucodynamics of Insulin Lispro in Normal Weight or Healthy Obese Subjects.
    de la Peña A; Yeo KP; Linnebjerg H; Catton E; Reddy S; Brown-Augsburger P; Morrow L; Ignaut DA
    J Diabetes Sci Technol; 2015 Jul; 9(4):824-30. PubMed ID: 25697717
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Subcutaneous tissue thickness in children with type 1 diabetes.
    Shin H; Kim MJ
    J Adv Nurs; 2006 Apr; 54(1):29-34. PubMed ID: 16553688
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Therapeutically equivalent pharmacokinetic profile across three application sites for AG200-15, a novel low-estrogen dose contraceptive patch.
    Stanczyk FZ; Archer DF; Rubin A; Foegh M
    Contraception; 2013 Jun; 87(6):744-9. PubMed ID: 23228503
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pegvisomant bioavailability of single 30 mg/mL subcutaneous injection compared to two 15 mg/mL subcutaneous injections: a pharmacokinetic, safety and tolerability study.
    Jen J; LaBadie RR; Liang Y; Crownover PH; Gao X; Hey-Hadavi JH
    Growth Horm IGF Res; 2013 Aug; 23(4):114-9. PubMed ID: 23651793
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical efficacy and safety of once-weekly glucagon-like peptide-1 agonists in development for treatment of type 2 diabetes mellitus in adults.
    Tzefos M; Harris K; Brackett A
    Ann Pharmacother; 2012 Jan; 46(1):68-78. PubMed ID: 22232377
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The pharmacokinetics of recombinant human erythropoietin after subcutaneous injection at different sites.
    Jensen JD; Jensen LW; Madsen JK
    Eur J Clin Pharmacol; 1994; 46(4):333-7. PubMed ID: 7957518
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of varying degrees of renal impairment on the pharmacokinetics and tolerability of taspoglutide.
    Giraudon M; Sturm S; Lambert N; Niggli M; Brumm J; Mangold B; Schmitt C
    Diabetes Obes Metab; 2017 Apr; 19(4):537-544. PubMed ID: 27981717
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Implications of different application sites on the bioavailability of a transdermal contraceptive patch containing ethinyl estradiol and gestodene: an open-label, randomized, crossover study.
    Höchel J; Schuett B; Ludwig M; Zurth C
    Int J Clin Pharmacol Ther; 2014 Oct; 52(10):856-66. PubMed ID: 25138681
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacokinetics of a new subcutaneous diclofenac formulation administered to three body sites: quadriceps, gluteus, and abdomen.
    Salomone S; Piazza C; Vitale DC; Cardì F; Gugliotta B; Drago F
    Int J Clin Pharmacol Ther; 2014 Feb; 52(2):129-34. PubMed ID: 24361086
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Single-center, single-dose, open-label, randomized, two-period crossover study on the bioavailability of methotrexate administered using a novel prefilled, needle-free delivery system.
    Bienvenu B; Aouba A; Gottenberg JE; Verstuyft C
    Curr Med Res Opin; 2017 Apr; 33(4):605-611. PubMed ID: 27874307
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The abdomen, thigh, and arm as sites for subcutaneous sodium heparin injections.
    Fahs PS; Kinney MR
    Nurs Res; 1991; 40(4):204-7. PubMed ID: 1857645
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacokinetic comparisons between two formulations containing 100 mg of miglitol in healthy male Korean volunteers: a randomized, open-label, single-dose, two-period, two-sequence crossover bioequivalence study.
    Choi HG; Jeon JY; Im YJ; Kim Y; Jang H; Kang S; Kim KH; Chae SW; Lee SY; Kim MG
    Int J Clin Pharmacol Ther; 2014 Jan; 52(1):55-63. PubMed ID: 24290415
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bioavailability of two sublingual formulations of ketorolac tromethamine 30 mg: a randomized, open-label, single-dose, two-period crossover comparison in healthy Mexican adult volunteers.
    Galán-Herrera JF; Poo JL; Maya-Barrios JA; de Lago A; Oliva I; González-de la Parra M; Jiménez P; López-Bojórquez E; Burke-Fraga V; Namur S
    Clin Ther; 2008 Sep; 30(9):1667-74. PubMed ID: 18840372
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of the Pharmacokinetics of the Phase II and Phase III Capsule Formulations of Selumetinib and the Effects of Food on Exposure: Results From Two Randomized Crossover Trials in Healthy Male Subjects.
    Tomkinson H; McBride E; Martin P; Lisbon E; Dymond AW; Cantarini M; So K; Holt D
    Clin Ther; 2017 Nov; 39(11):2260-2275.e1. PubMed ID: 28985960
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical Pharmacokinetics of Dulaglutide in Patients with Type 2 Diabetes: Analyses of Data from Clinical Trials.
    Geiser JS; Heathman MA; Cui X; Martin J; Loghin C; Chien JY; de la Peña A
    Clin Pharmacokinet; 2016 May; 55(5):625-34. PubMed ID: 26507721
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Bioequivalence of Canakinumab Injected Subcutaneously via an Autoinjector Device or a Prefilled Safety Syringe Device in Healthy Subjects.
    Anumolu SS; Lindgren S; Vemula J; Floch D; Reynolds C; Wallny HJ; Sun H
    Clin Pharmacol Drug Dev; 2018 Nov; 7(8):829-836. PubMed ID: 29676864
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The Absorption of Needle-Free Insulin Aspart Through Jet Injector in Different Body Parts of Healthy Individuals.
    Pan Q; Zhang L; Gu A; Yu D; Wang X; Zhou Y; Guo L
    Front Endocrinol (Lausanne); 2022; 13():832726. PubMed ID: 35574009
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Investigation of bioequivalence of a new fixed-dose combination of acarbose and metformin with the corresponding loose combination as well as the drug-drug interaction potential between both drugs in healthy adult male subjects.
    Kim S; Jang IJ; Shin D; Shin DS; Yoon S; Lim KS; Yu KS; Li J; Zhang H; Liu Y; Brendel E; Blode H; Wang Y
    J Clin Pharm Ther; 2014 Aug; 39(4):424-31. PubMed ID: 24806030
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Intramuscular risk at insulin injection sites--measurement of the distance from skin to muscle and rationale for shorter-length needles for subcutaneous insulin therapy.
    Hirsch L; Byron K; Gibney M
    Diabetes Technol Ther; 2014 Dec; 16(12):867-73. PubMed ID: 25329935
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.